1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

With $36bn from Teva, what should Allergan buy next?

 
• By Mandy Jackson

Allergan left all options on the table in terms of the types of deals that the ever-growing company will pursue with its $36bn in after-tax proceeds from the $40.5bn sale of its generics business to Teva Pharmaceutical Industries.

Allergan left all options on the table in terms of the types of deals that the ever-growing company will pursue with its $36bn in after-tax proceeds from the $40.5bn sale of its generics business to Teva Pharmaceutical Industries.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 
• By Sushmita Panda

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By Xu Hu

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.